ANTISENSE PHARMA is an innovative biotech company aimed at developing and marketing novel antisense technology based drugs for the treatment of cancer and other so far incurable diseases.
Founded in Göttingen 1998, the company is now headquartered in the BioPark in Regensburg, one of the most prominent Biotech centers in Germany. ANTISENSE PHARMA is run by corporate executives with a strong track record in both scientific expertise and entrepreneurial biotechnology. They are supported by a highly professional staff with a strong pharmaceutical as well as clinical background and experience in business.
ANTISENSE PHARMA develops antisense drugs that specifically block the production of key proteins responsible for the onset and progression of diseases such as cancer. This approach represents a novel therapeutic modality by which diseases are rather tackled directly at their pathogenic cause than by merely combating their effects. Antisense Pharma drugs are specifically targeted at pre-selected proteins such as TGF-beta. Thus the company`s approach is unique in the field of antisense drug development.
The lead product of ANTISENSE PHARMA is AP 12009. It has been developed to activate the body’s own immune system against highly malignant tumors. It currently is in an advanced stage of clinical testing. A solid international patent portfolio includes this drug and further candidate antisense compounds as well as various target proteins.
Recent Publications by ANTISENSE PHARMA GmbH: |  |
Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009.
TGF-beta overexpression is a hallmark of various malignant tumors. This is... | 30th January, 2009
| Antisense Pharma GmbH, Josef-Engert-Str. 9, 93053 Regensburg, Germany.
| Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):129-39. Epub 2005 Dec 27.
DOI Direct Link |
Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors.
Overexpression of the cytokine transforming growth factor-beta 2... | 16th January, 2008
| Antisense Pharma GmbH, Regensburg, Germany.
| Recent Results Cancer Res. 2008;177:137-50.
|
Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety.
Here, we provide first evidence that long-term continuous infusion of... | 27th October, 2006
| Antisense Pharma GmbH, Regensburg, Germany.
| Oligonucleotides. 2005 Summer;15(2):94-104.
DOI Direct Link |
TGFbeta in cancer and other disease - AACR special conference in cancer research.
Overexpression of the cytokine transforming growth factor-beta 2... | 26th July, 2006
| Antisense Pharma GmbH, Josef-Engert-Strasse 9, D-93053 Regensburg,
| IDrugs. 2006 Apr;9(4):239-41.
|
The reading frame BPLF1 of Epstein-Barr virus: a homologue of herpes simplex virus protein VP16.
The open reading frame BPLF1 of Epstein-Barr virus (EBV) shows homology to... | 26th January, 2005
| Antisense Pharma GmbH, Josef-Engert-Strasse 9, D-93053 Regensburg,
| Virus Genes. 2004 Oct;29(2):267-77.
DOI Direct Link |
→View more ANTISENSE PHARMA GmbH research publications. |
This page has been viewed 784 times since April 2007, the link to the organisation's website has been followed 118 times
